---
title: "Epstein–Barr virus mechanisms driving autoimmunity: shared pathways and disease-specific vulnerabi"
id: "frontiers-in-immunology-12-mechanisms-of-epstein-barr-virus-associated-autoimmunity-a-comparative-overview"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-mechanisms-of-epstein-barr-virus-associated-autoimmunity-a-comparative-overview"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1891373"
published_at: "2026-07-21T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Epstein–Barr virus mechanisms driving autoimmunity: shared pathways and disease-specific vulnerabi
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-mechanisms-of-epstein-barr-virus-associated-autoimmunity-a-comparative-overview
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1891373)
- **Published At:** 2026-07-21T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Epstein–Barr virus (**EBV**) is a ubiquitous herpesvirus infecting most adults and is increasingly implicated as a modifier in autoimmune diseases including **multiple sclerosis (MS)**, **systemic lupus erythematosus (SLE)**, and **rheumatoid arthritis (RA)**. - EBV lifecycle features latency in B cells with defined latency programs (0, I, II, III) and periodic lytic reactivation; latent gene products and noncoding RNAs persist and influence host immunity. - Latent proteins such as **EBNA1**, **LMP1**, **LMP2**, and **EBNA2** have conserved roles across diseases: EBNA1 is consistently expressed and elicits cross-reactive immune responses; LMP1 acts as a CD40 mimic promoting constitutive B-cell activation; LMP2A alters antigen presentation and BCR–TLR signaling; EBNA2 modulates transcription at loci linked to autoimmune risk. - **Molecular mimicry** between short viral peptides and host proteins is a central shared mechanism; specific host targets differ by disease (e.g., GlialCAM/Myelin proteins in MS; Sm, Ro, dsDNA in SLE; synovial and collagen targets in RA). - EBV infection of **autoreactive B-cells** can rescue these cells from tolerance checkpoints, promote their survival as latently infected memory B-cells, and convert them into antigen-presenting cells that sustain autoreactive T-cell responses and autoantibody production. - Dysregulation of **type 1 interferon (IFN-1)** pathways is triggered by EBV nucleic acids and proteins via PRRs (TLRs, RIG-I–like receptors, cGAS–STING) and contributes to systemic inflammation; IFN-targeted therapies in SLE support IFN-1’s pathogenic role. - Disease-specific patterns arise from tissue localization of infected cells and immune responses: CNS-compartmentalized responses, meningeal tertiary lymphoid structures and EBNA1–neural mimicry in MS; higher systemic viral load, recurrent reactivation and multi-antigen mimicry in SLE; synovial persistence, ectopic lymphoid structures and enhanced anti-citrullinated responses in RA. - Timing of primary infection (delayed infection/IM) and host genetics, especially **HLA** alleles that shape antigen presentation and T-cell responses, modulate susceptibility and disease phenotype. - EBV functions as a context-dependent immunological modifier rather than a uniform trigger; multiple viral, host and environmental factors determine whether infection leads to autoimmunity. - Translational implication: dissecting these shared and disease-specific mechanisms could guide targeted preventive and therapeutic strategies for EBV-associated autoimmune conditions.
## Clinical Analysis & Structured Key Points
About us All journals All articles Submit manuscript Submit data Search Frontiers in Immunology Sections Articles Research Topics Editorial board About journal Published in Frontiers in Immunology Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders 7 impact factor 11.3 citescore Part of a Research Topic Evolution of Theories in Autoimmune Disease: From Early Concepts to Modern Integrations Submission open 28k views 16 articles Editor & Reviewers Edited by N T Nicole Trier Reviewed by A T Alberto Tommasini R R Ranjan Ramasamy Outline Abstract 1 Introduction 2 Shared mechanisms in EBV-driven autoimmunity 3 Disease-specific mechanisms: selective vulnerabilities 4 Role of HLA in EBV mediated autoimmunity 5 Conclusion Author contributions Funding Conflict of interest Generative AI statement Publisher’s note References Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Proteins involved in molecular mimicry in MS, SLE and RA. View in article Table 2 Molecular mimicry between major lupus associated autoantigens and EBV EBNA1 epitopes. View in article REVIEW article Front. Immunol., 21 July 2026 Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1891373 Mechanisms of Epstein-Barr virus-associated autoimmunity: a comparative overview F S Fathima Shabnam 1 G K Gulfaraz Khan 1,2* 1. Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates 2. Zayed Bin Sultan Center for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates Abstract Epstein–Barr virus (EBV) is a ubiquitous herpesvirus, increasingly implicated in the pathogenesis of several autoimmune diseases, such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). These diseases have both, shared and disease-specific immunopathogenic pathways involving EBV. Shared mechanisms include the role of EBV latent proteins in triggering immune dysfunction, molecular mimicry between viral and self-antigens, infection of autoreactive B-cells, and dysfunction of type 1 interferon (IFN-1) responses. In MS, EBV is associated with a CNS-compartmentalized CD8+ T-cell responses, molecular mimicry with neural antigens, and formation of meningeal tertiary lymphoid structures. In SLE, EBV contributes to systemic autoimmunity through mimicry with multiple autoantigens, recurrent viral reactivation, and IFN-driven multi-organ inflammation. In RA, EBV promotes the formation of synovial ectopic lymphoid structures, enhances anti-citrullinated protein antibody production, and drives proinflammatory cytokine dysregulation. Host genetic variations, particularly in HLA alleles, further modulate susceptibility by influencing antigen presentation, viral control and autoreactive T-cell responses. Rather than acting as a uniform and consistent trigger, EBV appears to function as a context-dependent immunological modifier whose pathogenic effects are influenced by factors such as the timing of infection, tissue microenvironment, HLA-associated genetic background, and other environmental exposures. Unravelling the details of these mechanisms may inform targeted preventive and therapeutic strategies for EBV-associated autoimmune diseases. 1 Introduction Epstein-Barr Virus (EBV), also known as human herpesvirus 4 (HHV-4), is arguably one of the most ubiquitous human viruses, infecting at least 90% of adults worldwide (1). It was first isolated from a case of Burkitt’s lymphoma in 1964, indicating that this virus could be oncogenic, a notion which was subsequently shown to be correct (2). A few years later, another dimension to EBV emerged when researchers unexpectedly found an association between the virus and autoimmune diseases when studying lymphomas (3). This multifaceted behavior of EBV has ever since remained an area of scientific interest. Structurally, EBV, like other herpesviruses, is composed of a lipid envelope, tegument, and nucleocapsid (4). The outer lipid bilayer contains viral glycoproteins that regulate cellular tropism and membrane fusion. Beneath the envelope lies a pleomorphic tegument layer including the capsid-associated tegument complex, which links the envelope to the nucleocapsid (4–6). The icosahedral nucleocapsid encloses a linear double-stranded DNA genome and several dozen microRNAs (7, 8). Following infection, annealing of terminal repeat sequences enables ligation of genomic ends, resulting in circularization of the viral genome and establishment of a nuclear episomal form. The life cycle of EBV is governed by dynamic interactions between the virus and the host immune system to initiate primary infection, establish latency, and periodic reactivation resulting in the production of new virions. Primary infection is usually asymptomatic in infancy and early childhood, whereas delayed exposure in adolescents and young adults via salivary exchange can result in infectious mononucleosis (“kissing disease”) (9). Other transmission routes include sexual contact, organ transplantation, and blood transfusion. Following infection, EBV establishes latency in circulating peripheral blood B-lymphocytes with restricted viral gene expression and minimal virion production, enabling the virus to evade the immune system and establish life-long persistence (10). In infected B-cells, EBV can express up to six Epstein-Barr nuclear antigens (EBNA1, 2, 3A/3, 3B/4, 3C/6 and -LP), three latent membrane proteins (LMP1, 2A and 2B), two small noncoding RNAs (EBER1 and EBER2) and several dozen microRNAs (11–13). Based on the gene expression profiles, four different viral latency programs - latency 0, I, II, and III are recognized (Figure 1). Latency 0 is typically found in memory B-cells and is characterized by the expression of only EBERs. In latency I, EBERs and EBNA1 are expressed. Latency II is characterized by EBERs, EBNA1, LMP1, and LMP2. Latency III shows the broadest expression pattern, adding EBNA2, EBNA3, and EBNA-leader protein (EBNA-LP) to the proteins expressed in latency II (14). Reactivation occurs when EBV enters the replicative cycle marked by the expression of lytic genes, including its own transcription factor and DNA polymerase catalytic subunit, which results in amplification of its genome by more than a 100 fold (15). The process is initiated by transcriptional activation of BZLF1 and BRLF1, the corresponding protein products of which function as transcription activators, thereby triggering the initial lytic stimulus (16). Figure 1 EBV gene expression in B-cells and potential role in autoimmunity. EBV infects B-cells via the binding of the envelop glycoprotein gp350 with cellular CD21/C3d receptor. The virus can infect naïve IgM positive B-cells. In these cells the virus can expression a range of different latent proteins as well as non-coding RNAs (EBERs) and miRNAs. In immunocompetent hosts, naïve cells can differentiate into memory B-cells in lymphoid tissues and the virus establishes life-long latency. On reactivation, the virus expresses a limited set of latent proteins including EBNA1, EBNA2 and LMP1. Some of these proteins have been implicated in the pathogenesis of autoimmune diseases like MS, SLE and RA. All the immunohistochemistry (IHC) and EBER in situ hybridization (EBER-ISH) staining were performed on rabbit spleen tissues (17). Individual stained cells were cropped from the larger images and used to produce this figure. In addition to the well-established etiological role of EBV in malignancies, accumulating and creditable evidence indicates that this virus is also involved in the pathogenesis of several autoimmune diseases, including multiple sclerosis (MS) (18–20), lupus erythematosus (SLE) (21, 22) and rheumatoid arthritis (RA) (23). A recent landmark longitudinal study provided compelling evidence for a strong association between EBV infection and the subsequent development of MS (18). The study involved testing more than 10 million active US military personnel over a course of 20 years. During this period, 801 individuals developed MS, 35 of which were initially EBV seronegative, but all seroconverted before the onset of MS, except for one case. Thus, EBV infection increased the risk of MS by 32-fold. No such risk was found with CMV or other viruses (18). However, it is important to note that EBV infection alone is insufficient to cause MS, as the vast majority of EBV infected individuals never develop the disease. It appears that EBV acts within a complex network of genetic, environmental, and immunological factors, functioning as a trigger or disease modifier in susceptible individuals (24). Recognizing this distinction is important for interpreting epidemiological associations and developing effective preventive strategies. Understanding why this common virus triggers some individuals to develop MS, while others to develop SLE, RA, or remain disease-free despite lifelong infection remains unresolved. Thus, a comprehensive and comparative framework examining shared versus disease-specific EBV-driven pathogenic mechanisms is of interest. This review examines the association between EBV and three autoimmune diseases - SLE, RA, and MS, focusing on the underlying molecular mechanisms. 2 Shared mechanisms in EBV-driven autoimmunity 2.1 EBV latent proteins as common triggers 2.1.1 EBNA1 as a universal autoimmune initiator Amongst the several lytic and latent EBV gene products, the latency-associated EBNA1 is the only protein consistently expressed in infected B-cells in healthy carriers (25). Interestingly, all three diseases (MS, SLE, RA) demonstrate elevated antibody responses to EBNA1, indicating this protein to be a potential shared trigger of autoimmunity (26). EBNA1 employs multiple mechanisms to prevent presentation of its peptides on the surface of EBV-infected B-cells (27). However, its large glycine–alanine repeat domain promotes T-cell independent antibody responses that facilitate epitope spreading (28). More recently, it was reported that EBNA1-specific CD4+ T-cells can cross-react with MS autoantigen ANO2, thereby leading to EBV-mediated neuroinflammation and MS pathology (29). This EBNA1-specific heteroimmune responses appear particularly important because this protein is expressed in all EBV-infected B-cells in latency programs I-III, suggesting that it may be a trigger for immune dysregulation. 2.1.2 LMP1 and LMP2 - CD40 like mimicry and B-cell dysfunction LMP1, initially noted for its oncogenic activity, is also known for functioning as a CD40 homolog and represents a key functional mimic driving aberrant B-cell activation across autoimmune diseases (30). Unlike CD40, which requires CD154-mediated trimerization for activation, LMP1 self-aggregates through its six transmembrane domains in a ligand-independent manner, driving constitutive downstream signaling, promoting B-cell activation, germinal center formation, and antibody and cytokine production (31). It also upregulates activation-induced cytidine deaminase (AID) which drives polyclonal B-cell activation and class-switching recombination, rescuing autoreactive B-cells from apoptosis and promoting auto-antibody production across multiple diseases (32). By signaling independently of T-cell–derived CD154, LMP1 enables constitutive B-cell activation, a mechanism that may facilitate immune evasion and drive the loss of immune tolerance, leading to autoimmunity. In SLE specifically, LMP1 expression in the context of EBNA1 molecular mimicry amplifies immune dysregulation, promoting enhanced cellular and humoral responses that cross-react with lupus autoantigens (particularly Sm) (30). Additionally, LMP2A has been reported to enhance the antigen presenting function of B-cells, which increases autoreactive T-cell activation, promotes inflammation and facilitates disease progression in the animal model of experimental autoimmune encephalomyelitis (EAE) (33). LMP2A also induces anti-Sm B-cell responses, enhances B-cell sensitivity to toll like receptor (TLR) stimulation, and influences plasma cell differentiation of otherwise regulated B-cells. By lowering the activation threshold through augmented B-cell receptor (BCR)-TLR signaling, LMP2A facilitates the survival and activation of autoreactive B-cells, ultimately promoting autoantibody production, and contributing to EBV-associated autoimmune diseases (34). 2.1.3 EBNA2: transcriptional activation and viral persistence EBNA2 is the principal transcriptional activator during EBV latency. Activating the EBV Cp promoter regulates the expression of other EBNAs, as well as the LMP1 promoter (35). It interacts with several transcription factors and binds to a large proportion of genetic loci associated with autoimmune disease risk. Notably, NF-κB subunits such as RELA, RELB, NFKB1, and NFKB2 significantly overlap with these regions, highlighting a potential role for EBNA2-mediated NF-κB signaling in driving susceptibility to inflammatory autoimmune disorders (36). 2.2 Molecular mimicry in autoimmunity Mimicry of host protein structures is a common mechanism employed by viruses to evade the host’s immune system (37). However, for such mimicry to be evolutionarily favorable, the benefits must outweigh the costs, such as longer replication time due to increased protein length, or potential loss of function arising from mutations required to achieve mimicry (mimicry trade-off hypothesis) (38). To combat this, viruses employ short peptide sequences, typically 3 to 10 amino acids long, to mimic host cellular motifs to allow effective immune evasion and limit negative impacts on protein function or length. This is referred to as short linear mimicry, a process that offers an optimal solution to the mimicry trade-off, and benefits viral survival (39, 40). Viruses belonging to the Herpesviridae and Poxviridae families have been shown to exhibit this type of mimicry (37). That said, unlike herpesviruses, poxviruses do not seem to be associated with any autoimmune disease. This is explained by their tendency to mimic a narrower set of host proteins due to its targeting of longer and accurate mimics, while herpesviruses like EBV, appear to target short and low accuracy mimics. In other words, poxviruses mimic precisely but selectively whereas herpesviruses mimic broadly but imperfectly, and that broader mimicry may disrupt immune tolerance to a greater extent. Coupled with this is the ability of herpesviruses to establish latency, which increases the frequency of targeting cross-reactive epitopes, and thereby the likelihood of autoimmune sequelae. It has also been reported that EBV latent proteins display significantly more mimicry than those expressed during the lytic phase. However, this observation is not universal to all herpesviruses; HHV8 and CMV appear to display high levels of mimicry in both, their latent and lytic proteins (37). Even though molecular mimicry between the various EBV epitopes and host antigens represent a fundamental shared mechanism across several autoimmune disorders, the specific host targets differ dramatically by disease (Table 1). This divergence suggests that although the viral mimicry mechanism is central to autoimmunity, it is the tissue-specific distribution of corresponding host proteins that largely dictate the disease phenotype. Table 1 Disease EBV component Host proteins References Multiple Sclerosis (MS) EBNA1 GlialCAM, myelin basic protein, αB-crystallin, anoctamin-2 (20, 29, 41, 42) Systemic Lupus Erythematosus (SLE) EBNA1 SmB, SmD, C1q, Ro, p542, dsDNA (43–48) Rheumatoid Arthritis (RA) EBNA1, EBNA2, vIL-10 Synovial membrane 62-kDa protein, cytokeratin and type II collagen, hIL-10 (49–51) Proteins involved in molecular mimicry in MS, SLE and RA. 2.3 Autoreactive B-cells and autoimmunity Early B-cell development includes a population of autoreactive naïve B-cells that are usually kept in check by central and peripheral B-cell tolerance checkpoints. Central B-cell tolerance in humans relies on proper BCR and TLR signaling and function, while the peripheral B-cell tolerance checkpoints depends on T-cells/Tregs to prevent their accumulation and subsequent production of self-reactive antibodies (52). When EBV infects these autoreactive B-cells, it drives their proliferation and persistence as apoptosis-resistant, latently infected memory B-cells in genetically susceptible individuals. These cells accumulate in target organs, and act as antigen-presenting cells (53). Cross-reactive CD4+ T-cells activated in lymphoid tissues migrate to these sites, receive survival signals, and evade apoptosis, leading to sustained inflammation, cytokine production, and chronic tissue damage, as seen in autoimmune diseases (54). The subsequent antibody production in the host has been shown to exhibit three important features: IgM dominance facilitates target cell injury via activation of the classical complement pathway; ubiquitous immunoglobulin production independent of germinal centers or bone marrow; and rescue of autoreactive B-cells from checkpoints (55). All three processes skew the repertoire toward autoantibody production. Thus, EBV reprograms the autoreactive B-cells into activated antigen presenting cells. These cells in turn stimulate autoreactive helper T-cells, further activating more autoreactive B-cells, including uninfected ones. In this scenario, the B-cells effectively act like triggers that sets off an inflammatory cascade and orchestrate the activation of a systemic autoimmune response (56). 2.4 Type 1 interferon dysregulation Type 1 interferon (IFN-1) activation represents a pathogenic mechanism across MS, SLE, and RA. EBV nucleic acids and viral proteins trigger pattern recognition receptors (TLRs, RIG-I-like receptors, cGAS-STING pathway) leading to a dysregulated IFN-1 release (57). In fact, some TLRs are more specifically associated with some autoimmune diseases. For example, TLR2 or TLR4 polymorphisms are frequently associated with RA, while TLR5 and TLR8 polymorphisms are associated with SLE and Sjogren’s syndrome (58). IFN-targeting therapy in SLE has in fact shown positive results in phase II and III clinical trials, underscoring its pathogenic role in autoimmunity (59–61). 3 Disease-specific mechanisms: selective vulnerabilities Although MS, SLE, and RA share several EBV-driven pathogenic mechanisms that trigger an autoimmune response, disease-specific outcomes reflect the interplay between several viral, environmental, and host factors. Differences in the localization of persistent EBV infection, as seen in a compartmentalized immune response in CNS in MS, a higher systemic viral load in SLE and persistence within synovium in RA, may influence the tissues targeted by immune responses. Similarly, the timing of primary infection and immune status during viral reactivation can shape the magnitude of antiviral response. For example, delayed EBV infection to adolescence and the development of infectious mononucleosis (IM) has been consistently shown to be associated with 2-3-fold increase risk in MS (62, 63). Similar associations may also exist for SLE and RA, but the data is far less clear. Reports indicate that SLE is more frequent and more severe in immigrants of African and Asian origin living in Europe and North America (64, 65). Whether is this is due to delayed infection or underlying genetic susceptibility or other environmental factors is unclear (66–68). Finally, host genetic factors, particularly HLA-associated antigen presentation, help determine the specificity of autoreactive responses. Together, these factors provide a background for understanding how EBV-driven immune response can give rise to distinct autoimmune phenotypes. This complexity
## Related Clinical Research

- [CAR-T cell therapy in autoimmune diseases: progress, challenges, and emerging technologies](https://medichelpline.com/clinical-feed/plos-medicine-0-progress-and-promise-of-car-t-cell-treatment-in-autoimmune-diseases.md)
- [MicroRNAs in Immune-Related Diseases: Mechanisms, Functions and Therapeutic Perspectives](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-micrornas-in-immune-related-diseases-mechanism-functions-and-therapeutic.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [Emergency diagnosis frequency and outcomes across 13 non-cancer conditions in England: analysis of](https://medichelpline.com/clinical-feed/plos-medicine-2-frequency-and-prognostic-outcomes-of-emergency-diagnosis-in-13-non-neoplastic.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.